Affiliation:
1. Head & Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Abstract
ABSTRACT Fosbretabulin tromethamine is a vascular disrupting agent, which is a type of drug that is designed to damage the vasculature (blood vessels) of cancer tumors, causing central necrosis. This drug showed activity against anaplastic thyroid cancer that was demonstrated in orthotopic xenograft models as well as in Phase I/II trials with or without carboplatin and paclitaxel combination therapy. In all of these studies, fosbretabulin was well tolerated.
Subject
Cancer Research,Oncology,General Medicine
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献